AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11768322
Drug: 4g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g of ascorbic acid administered intravenously prior to induction
Trial: 11768322
Drug: 4g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g of ascorbic acid administered in the cardioplegic solution
Trial: 3148470
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg i.m.
Trial: 3148470
Drug: Ketorolac 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 90 mg i.m.
Trial: 29301824
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 (20 μg/day for 13 weeks, then 60 μg/day for 26 weeks)
Trial: 22638548
Drug: HbA1c ≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbA1c ≤ 6.4% (≤ 46 mmol/l)
Trial: 10684784
Drug: Carbamazepine 600-800
RxNorm normalized name: carbamazepine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 600-800 mg
Trial: 1290731
Drug: Continuing medical
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing medical treatment
Trial: 29782035
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet of rosuvastatin-ezetimibe
Trial: 29782035
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of rosuvastatin and ezetimibe
Trial: 27161611
Drug: Tocilizumab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (single dose prior to coronary angiography)
Trial: 23106871
Drug: TL-pulsed DC-CIK
RxNorm normalized name: TL-895
DrugBank: TL-895 (DB16471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TL-pulsed DC-CIK cells immunotherapy
Trial: 23106871
Drug: Interferon (IFN)-α
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN)-α immunotherapy
Trial: 18818130
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no postoperative adjuvant therapy)
Trial: 9744142
Drug: Budesonide Turbohaler
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide Turbohaler 400 micrograms once daily
Trial: 9744142
Drug: Budesonide Turbohaler
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide Turbohaler 200 micrograms twice daily
Trial: 7848948
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg intramuscularly before and after surgery
Trial: 3139698
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist and HMG
Trial: 30297663
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day n-3 LCPUFA as HiDHA™ tuna oil
Trial: 30297663
Drug: 0.35 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35 g/day n-3 LCPUFA as HiDHA™ tuna oil
Trial: 30297663
Drug: 0.7 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g/day n-3 LCPUFA as HiDHA™ tuna oil
Trial: 30297663
Drug: 0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/day n-3 LCPUFA (placebo - Sunola oil)
Trial: 26507926
Drug: Topical eflornithine
RxNorm normalized name: eflornithine Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eflornithine applied twice daily for 6 months
Trial: 26507926
Drug: No eflornithine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No eflornithine treatment (control)
Trial: 20842042
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) with transdermal contraceptive patch (ethinyl estradiol and norelgestromin)
Trial: 20842042
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) with oral contraceptive pill (ethinyl estradiol and norethindrone)
Trial: 20842042
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) with transdermal contraceptive patch
Trial: 18375093
Drug: rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.6 mg/kg + ephedrine 70 microg/kg (Group II)
Trial: 18375093
Drug: rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.6 mg/kg + 0.9% saline (Group IV)
Trial: 14670701
Drug: Compound stimuli
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound stimuli with element heterogeneity
Trial: 14670701
Drug: Compound stimuli
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound stimuli with element homogeneity
Trial: 1730278
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy MOCCA (vincristine, cyclophosphamide, lomustine, melphalan, methylprednisolone)
Trial: 1730278
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy MOCCA
Trial: 30328654
Drug: CRT-D (Cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D (Cardiac Resynchronization Therapy with a defibrillator)
Trial: 29802791
Drug: Everolimus +
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus + reduced-dose calcineurin-inhibitor
Trial: 22052627
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus low-level laser therapy (4 J/cm(2) at each point over a maximum of ten painful points for total 5 min duration)
Trial: 22052627
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus low-level laser therapy
Trial: 19864958
Drug: Perindopril and
RxNorm normalized name: perindopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril and Indapamide (active treatment)
Trial: 12792664
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (850-882 mg EPA and DHA as concentrated ethylesters)
Trial: 12792664
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (1 g)
Trial: 1611115
Drug: Intron A
RxNorm normalized name: Intron A
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intron A at 10 MU and mitomycin C (MMC) at 20 mg/instillation
Trial: 1611115
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) at 20 mg/instillation
Trial: 6377568
Drug: High-dose streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose streptokinase (100,000 U/h)
Trial: 6377568
Drug: Low-dose streptokinase
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose streptokinase (approx 10,000 U/h) with low-dose heparin
Trial: 30409926
Drug: Amorolfine 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorolfine 0.25% cream
Trial: 25090010
Drug: 2-hour psycho-education
RxNorm normalized name: MANGANESE DICATION
DrugBank: Manganese cation (DB06757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour psycho-education session combined with bi-weekly telephone support
Trial: 21419391
Drug: FRIENDS cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRIENDS cognitive‐behavioral therapy (CBT) intervention
Trial: 16849680
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori treatment (amoxicillin and omeprazole for 2 weeks)
Trial: 16849680
Drug: Garlic supplement
RxNorm normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplement (aged garlic extract and steam-distilled garlic oil for 7.3 years)
Trial: 16849680
Drug: Vitamin supplement
RxNorm normalized name: Vitamin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplement (vitamin C, vitamin E, and selenium for 7.3 years)
Trial: 11162751
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride (1200 mg/day, q.i.d. regimen)
Trial: 11162751
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride (800 mg/day, b.i.d. regimen)
Trial: 11162751
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride (600 mg/day)
Trial: 11162751
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride (1200 mg/day)
Trial: 1546820
Drug: Ketotifen, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen, 2 mg
Trial: 1546820
Drug: Clemastine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine, 1 mg
Trial: 1546820
Drug: Sodium cromoglycate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate, 10 mg
Trial: 3935589
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment by phenoxymethyl penicillin
Trial: 23274578
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg clopidogrel
Trial: 22921739
Drug: Half-dose Pneumococcal
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose Pneumococcal vaccination with exercise
Trial: 22921739
Drug: Full-dose Pneumococcal
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose Pneumococcal vaccination with exercise
Trial: 10214169
Drug: Multisensory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory therapy
Trial: 2121551
Drug: Protocol 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 2: daily GnRH‐a beginning in the midluteal phase, followed by 150 IU hMG after down regulation
Trial: 2121551
Drug: Protocol 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 1: 100 mg of clomiphene citrate on days 5 to 9, followed by 150 IU hMG beginning on day 9
Trial: 649030
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg domperidon t.i.d. for 4 weeks
Trial: 29273079
Drug: Early Structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Structured Physiotherapy with an intra-articular steroid injection
Trial: 29273079
Drug: Manipulation under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manipulation under anaesthesia with a steroid injection
Trial: 27084728
Drug: Tiotropium Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat 1.25 μg once daily
Trial: 27084728
Drug: Tiotropium Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat 2.5 μg once daily
Trial: 21948942
Drug: Subcutaneous adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous adalimumab 80 mg at baseline followed by 40 mg every other week for 1 year
Trial: 21948942
Drug: Intravenous infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infliximab 5 mg/kg
Trial: 21948942
Drug: Subcutaneous adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous adalimumab
Trial: 16113029
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine combined with chemotherapy
Trial: 11932879
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CSA and MTX)
Trial: 9474925
Drug: IL-3 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-3 at a dose of 5 micrograms/kg/day for 7 to 14 days
Trial: 9474925
Drug: IL-11 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-11 at a dose of 50 micrograms/kg/day for 14 days
Trial: 7535834
Drug: Single aural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single aural toilet and instillation of medicated ointment
Trial: 2709485
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral polio vaccine (TOPV), 5 doses at intervals of 4 weeks
Trial: 2709485
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral polio vaccine (TOPV), 2 doses
Trial: 2709485
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral polio vaccine (TOPV), 3 doses
Trial: 779704
Drug: Thioridazine hydrochloride
RxNorm normalized name: Thioridazine Hydrochloride
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine hydrochloride (15% to 50% of pretrial dose) combined with metyrosine
Trial: 31349690
Drug: Polygonatum sibiricum
RxNorm normalized name: POLYGONATUM SIBIRICUM ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polygonatum sibiricum (PS) rhizome extract (500 mg/day, n = 40)
Trial: 28848126
Drug: Other chemotherapy
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other chemotherapy group in the taxane group
Trial: 19506839
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg pramipexole
Trial: 19506839
Drug: 0.1875 mg
RxNorm normalized name: digoxin 0.1875 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1875 mg pramipexole
Trial: 19506839
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg pramipexole
Trial: 19506839
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg pramipexole
Trial: 19506839
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg pramipexole
Trial: 16686721
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg GYKI‐16084
Trial: 16686721
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg GYKI‐16084
Trial: 2183873
Drug: Didox 6
RxNorm normalized name: Digox
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didox 6 g m‐2 by 36 h infusion
Trial: 2183873
Drug: Didox 6
RxNorm normalized name: Digox
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didox 6 g m‐2 by 30 min infusion
Trial: 7463326
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of dexamethasone at 11 pm (Treatment A)
Trial: 7463326
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of dexamethasone at 11 pm (Treatment B)
Trial: 7463326
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of dexamethasone at 11 pm and an additional 1 mg at 6 am (Treatment C)
Trial: 29170998
Drug: Isotonic maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic maintenance fluid (NaCl 0.9% in glucose 5% with 40 mmol L‐1 potassium chloride)
Trial: 29170998
Drug: Hypotonic maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic maintenance fluid (premixed solution containing 54 mmol L‐1 sodium, 55 mmol L‐1 chloride and 26 mmol of potassium)
Trial: 22068990
Drug: No surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surgery (best medical therapy)
Trial: 16905810
Drug: Curiosin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curiosin and plasma-therapy
Trial: 15688984
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) treatment at a dose of 4 g/day i.v. for the first 24 hours after admission
Trial: 15688984
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without MgSO4
Trial: 11343038
Drug: Intravenous secretin
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous secretin (2.0 clinical units per kg as a single dose)
Trial: 9389261
Drug: suxamethonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 1.0 mg kg-1
Trial: 9389261
Drug: rocuronium 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.9 mg kg-1
Trial: 9389261
Drug: mivacurium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.1 mg kg-1 with rocuronium 0.3 mg kg-1
Trial: 9389261
Drug: mivacurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.15 mg kg-1 with rocuronium 0.45 mg kg-1
Trial: 9389261
Drug: mivacurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.2 mg kg-1
Trial: 9389261
Drug: rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.6 mg kg-1
Trial: 9389261
Drug: rocuronium 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.45 mg kg-1 and mivacurium 0.15 mg kg-1
Trial: 7893583
Drug: Idrapril calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idrapril calcium 100 mg twice daily
Trial: 7893583
Drug: Idrapril calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idrapril calcium 200 mg twice daily
Trial: 7893583
Drug: Idrapril calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idrapril calcium 400 mg twice daily
Trial: 7893583
Drug: Idrapril calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idrapril calcium (all doses)
Trial: 17906871
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg) plus visual sexual stimulation (VSS)
Trial: 10638606
Drug: Neostigmine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2.0 mg i.v. over 3-5 min
Trial: 10638606
Drug: Neostigmine (open-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (open-label treatment)
Trial: 1473540
Drug: Ceftazidime monotherapy
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime monotherapy (CAZ)
Trial: 30052230
Drug: Inhaled levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled levosimendan administered 6th hourly over 24 h
Trial: 30052230
Drug: Intravenous levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levosimendan infusion at 0.1 mcg/kg/min for 24 h
Trial: 30052230
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as the comparison between inhaled and intravenous levosimendan)
Trial: 24560584
Drug: Symbiotic Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic Drink (administered via enteral feeding during the first 7 days)
Trial: 9814627
Drug: Enalapril/hydrochlorothiazide (20/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril/hydrochlorothiazide (20/6 mg) daily
Trial: 9814627
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg) daily
Trial: 2503631
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (N=13)
Trial: 2503631
Drug: Lipid infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion (N=11)
Trial: 2503631
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (N=17)
Trial: 2503631
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) (N=10)
Trial: 21346607
Drug: ABT‐925 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐925 50 mg QD
Trial: 21346607
Drug: ABT‐925 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐925 150 mg QD
Trial: 17356091
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no inhaled medication)
Trial: 922328
Drug: 500 IU
RxNorm normalized name: Vitamin E 500 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 IU vitamin D daily